MAT-ES-2003538 v1.0 Abril 2021
1. Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with po- tential antirheumatic activity–I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 1985;7:7-18.
2. Drosos A. Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives? Drugs Aging 2003;20(10):723-36.
3. Case JP. Old and new drugs used in rheumatoid arthri- tis: a historical perspective. Part 2: the newer drugs and drug strategies. Am J Ther 2001;8(3):163-79.
4. Cush JJ. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am 2004;30(2):237-55.
5. Ranganath VK, Furst DE. Disease-modifying antirheu- matic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin N Am 2007;33:197-217.
6. Manna SK, Aggarwal BB. Immunosuppressive lefluno- mide metabolite (A77 1726) blocks TNF-dependent nu- clear factor-kappa B activation and gene expression. J Immunol 1999;162:2095-102.
7. Fox RI. Mechanism of action of leflunomide in rheuma- toid arthritis. J Rheumatol Suppl 1998;53:20-6.
8. Ruckermann K, Fairbanks LD, Carrey EA, Hawrylowi- cz CM, Richards DF, Kirschbaum B, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimu- lated T-lymphocytes from healthy humans. J Biol Chem 1998;273(34):21682-91.
9. Cherwinski HM, Cohn RG, Cheung P, Webster DJ, Xu YZ, Caulfield JP, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhi- biting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995;275:1043-9.
10. Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999;58(6):1137-64.
11. Xu X, Blinder L, Shen J, Gong H, Finnegan A, Williams JW, et al. In vivo mechanism by which leflunomide con- trols lymphoproliferative and auto immune disease in MRL/MpJ-Ipr/Ipr mice. J Immunol 1997;159:167-74.
12. Siva C, Eisen SA, Shepherd R, Cunningham F, Fang MA, Finch W, et al. Leflunomide use during the first 33 months after Food and Drug Administration approval: experience with a national cohort of 3,325 patients. Ar- thritis Rheum 2003;42:745-51.
13. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002;41:421-30.
14. Chong AS, Huang W, Liu W, Luo J, Shen J, Xu W, et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplanta- tion 1999;68:100-9.
15. Weinblatt M, Kremer J, Coblyn J, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and effi- cacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.
16. Li J, Yao H, Jin Y, Zhang YF, Li CY, Li YH, et al. Pharma- cokinetics of leflunomide in Chinese healthy volunteers. Acta Pharmacol Sin 2002;23:551-5.
17. Keen HI, Conaghan PG, Tett SE. Safety evaluation of le- flunomide in rheumatoid arthritis. Expert Opin Drug Saf 2013;12:581-8.
18. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and metho- trexate. Arch Intern Med 1999;159:2542-50.
19. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Ol- sen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflu- nomide compared with methotrexate. Arthritis Rheum 2001;44:1984-992.
20. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic pro- gression of rheumatoid arthritis. Results from three randomized controlled trials of leflunomide in pa- tients with active rheumatoid arthritis. Arthritis Rheum 1999;43:495-505 [erratum: Arthritis Rheum 2000;43:1345].
21. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulophasalazine in active rheumatoid arthritis: a double-blind, randomized, multi- center trial. Lancet 1999;353:259-66.
22. Scott DL, Smolen JS, Kalden JR, van de Putte LB, Lar- sen A, Kvien TK, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001;60:913-23.
23. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, et al. A comparison of the effi- cacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000;39:655-65.
24. Alcorn N, Saunders S, Madhok R. Benefit-risk as- sessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009;32:1123-34.
25. van Riel PL, Smolen JS, Emery P, et al. Leflunomide: a manageable safety profile. J Rheumatol Suppl 2004;71: 21-24.
26. Van Roon EN, Jansen TL, Houtman NM, Spoelstra P, Brouwers JR. Leflunomide for the treatment of rheuma- toid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 2004;27:345-52.
27. Cassina M, Johnson DL, Robinson LK, Braddock SR, Xu R, Jimenez JL, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Ar- thritis Rheum 2012;64:2085-94.
28. Sevilla-Mantilla C, Ortega L, Agúndez JA, Fernández- Gutiérrez B, Ladero JM, Díaz-Rubio M. Leflunomide induced acute hepatitis. Dig Liver Dis 2004;36(1):82-4.
29. Takeishi M, Akiyama Y, Akiba H, Adachi D, Hirano M, Mimura T. Leflunomide-induced acute interstitial pneu- monia. J Rheumatol 2005;32:1160-3.
30. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Ar- thritis Rheum 2006;54:1435-9.
31. Smolen JS, Landewe R, Bijlsma J, Burmester G, Cha- tzidionysiou K, Dougados M, et al. EULAR recommen- dations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antir- heumatic drugs: 2016 update. Ann Rheum Dis 2017; 76(6):960-77.
32. Osiri M, Shea B, Welch V, Suarez-Almazor ME, Strand V, Tugwell P, et al. Leflunomide for the treatment of rheu- matoid arthritis. Cochrane Database Syst Rev 2003;(1): CD002047.
33. Amit M, Rakhee M. A comparative 3-year clinical study of combined leflunomide and methotrexate vs metho- trexate alone as DMARD in rheumatoid arthritis. The Journal of Rheumatology 2006;9 Suppl 1:A190.
34. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, et al. Combination leflunomide and metho- trexate therapy for patients with active rheumatoid ar- thritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 2004;31:1521-31.
35. Lao ZY, Ni LQ, Zhang ZF, Zhou JL, Chen L, Zhang F, et al. Leflunomide in treating rheumatoid arthritis: a double-blind study. Chinese Journal of New Drugs and Clinical Remedies 2001;20:94-7.
36. Amit M. A comparative 2-year clinical study of combi- ned leflunomide and methotrexate vs methotrexate alo- ne as DMARD in rheumatoid arthritis. Abstract book, the 11th APLAR meeting, Jeju, South Korea. Seoul, Sep 2004:2093.
37. Antony T, Jose VM, Paul BJ, Thomas T. Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis. Indian J Med Sci 2006;60:318-26.
38. Dougados M, Emery P, Lemmel EM, de la Serna R, Zer- bini CA, Brin S, et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in pa- tients with active rheumatoid arthritis: RELIEF 6-month data. J Rheumatol 2003;30:2572-9.
39. Wislowska M, Jakubicz D. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF- alpha blocker plus methotrexate versus methotrexate or leflunomide alone. Rheumatol Int 2007;27: 641-7.
40. Mariette X, Bijlsma JWJ, Herold M, Eiselstein J, Spen- cer-Green GT, Kupper H. Efficacy evaluation of adalimu- mab (Humira®) in combination with single and multiple disease modifying antirheumatic drugs in the REACT trial. Annals of the Rheumatic Diseases 2004;63 Suppl 1:278.
41. Finckh A, Dehler S, Gabay C. The effectiveness of leflu- nomide as a co-therapy of tumour necrosis factor inhi- bitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2009;68(1):33-9.
42. De Stefano R, Frati E, Nargi F, Baldi C, Menza L, Ham- moud M, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti- TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol [Internet] 2010;29(5):517-24.
43. Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination
Actualidad Científica
Artritis Reumatoide
Actualiza tus conocimento sobre la Artritis Reumatoide
Contenido Relacionado
La información contenida en este sitio web está dirigida exclusivamente a profesional sanitario facultado para prescribir o dispensar medicamentos en España (requiere una formación especializada para su correcta interpretación).
Sanofi promueve la prescripción de sus productos farmacéuticos en las condiciones establecidas en su ficha técnica.
Pulse ACEPTAR si usted es profesional sanitario en España y desea continuar en este sitio o SALIR para ser redirigido al sitio web de Sanofi.
campus.sanofi.es dice:
Hola, queremos avisarte que estás a punto de abandonar una web de Sanofi y accederás a otra página
web donde no se aplica nuestra política de privacidad. Sanofi no se hace responsable del contenido de dicha web externa.